Meta-hallmarks of aging and cancer

Cell Metabolism, Journal Year: 2023, Volume and Issue: 35(1), P. 12 - 35

Published: Jan. 1, 2023

Language: Английский

---

Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance

Cancer Cell, Journal Year: 2021, Volume and Issue: 40(2), P. 185 - 200.e6

Published: Dec. 23, 2021

Language: Английский

---

The coming decade in precision oncology: six riddles

Nature reviews. Cancer, Journal Year: 2022, Volume and Issue: 23(1), P. 43 - 54

Published: Nov. 24, 2022

Language: Английский

---

Mechanisms driving the immunoregulatory function of cancer cells

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(4), P. 193 - 215

Published: Jan. 30, 2023

Language: Английский

---

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: Oct. 8, 2022

Abstract The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, gene therapy products) have approved as new molecular entities (NMEs) or biologics license applications (BLAs). A total of 228 these were identified cancer therapeutics cancer-related drugs, 120 them classified therapeutic for solid tumors according to their initial indications. These evolved from small molecules with broad-spectrum antitumor properties early stage monoclonal antibodies (mAbs) antibody‒drug conjugates (ADCs) more precise targeting effect during most recent decade. extended indications other malignancies, constituting treatment system monotherapy combined therapy. However, available targets are still mainly limited receptor tyrosine kinases (RTKs), restricting development drugs. In this review, summarized indications, characteristics, functions. Additionally, RTK-targeted therapies immune checkpoint-based immunotherapies also discussed. Our analysis existing challenges potential opportunities may advance tumor future.

Language: Английский

---

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(4), P. 906 - 916

Published: March 13, 2023

Language: Английский

---

Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis

Microbiome, Journal Year: 2022, Volume and Issue: 10(1)

Published: June 16, 2022

Abstract Background The gut microbiota is reportedly involved in the progression and chemoresistance of various human malignancies. However, underlying mechanisms behind how it exerts some effect on prostate cancer, as an extra-intestinal tumor, a contact-independent way remain elusive deserve exploration. Antibiotic exposure, one factors affecting community capable causing dysbiosis, associated with multiple disorders. This study aims to preliminarily clarify link between dysbiosis cancer. Results First, we discovered that perturbing by consuming broad-spectrum antibiotics water promoted growth subcutaneous orthotopic tumors mice. Fecal transplantation could transmit antibiotic exposure tumor growth. Then, 16S rRNA sequencing for mouse feces indicated relative abundance Proteobacteria was significantly higher after exposure. Meanwhile, intratumoral lipopolysaccharide (LPS) profoundly increased under elevation permeability. Both vivo vitro experiments revealed NF-κB-IL6-STAT3 axis activated LPS facilitated cancer proliferation docetaxel chemoresistance. Finally, patients’ fecal samples enriched patients metastatic positively correlated plasma IL6 level, regional lymph node metastasis status, distant status. receiver operating characteristic (ROC) curves showed had better performance than prostate-specific antigen (PSA) level predicting probability (area ROC curve, 0.860; p < 0.001). Conclusion Collectively, this research demonstrated characterized enrichment due resulted permeability LPS, promoting development via Considering findings from patients, might act intestinal biomarker progressive

Language: Английский

---

Immunology and immunotherapy of cholangiocarcinoma

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(6), P. 349 - 365

Published: Jan. 25, 2023

Language: Английский

---

The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells

Cancer Cell, Journal Year: 2023, Volume and Issue: 41(11), P. 1927 - 1944.e9

Published: Sept. 21, 2023

Language: Английский

---

Current understanding of the intratumoral microbiome in various tumors

Cell Reports Medicine, Journal Year: 2023, Volume and Issue: 4(1), P. 100884 - 100884

Published: Jan. 1, 2023

•Intratumoral microbes have been revealed to exist in many cancers•Intratumoral affect the host immune and tumor chemotherapy•The characteristics roles of intratumoral tumors were summarized•Exploring biomarkers for diagnosis, treatment, prognosis It is estimated that future, number new cancer cases worldwide will exceed 19.3 million recorded 2020, deaths 10 million. Cancer remains leading cause human mortality lagging socioeconomic development. Intratumoral types, including pancreatic, colorectal, liver, esophageal, breast, lung cancers. microorganisms not only system, but also effectiveness chemotherapy. This review concentrates on various tumors. In addition, potential therapies targeting microbes, as well main challenges currently delaying these therapies, are explored. Furthermore, we briefly summarize existing technical methods used characterize microbes. We hope provide ideas exploring targets prognostication.

Language: Английский

---